Healthcare diagnostics company Quest Diagnostics (NYSE: DGX) will be reporting results this Tuesday before market open. Here’s what investors should know.

Quest beat analysts’ revenue expectations last quarter, reporting revenues of $2.81 billion, up 7.1% year on year. It was a very strong quarter for the company, with full-year revenue guidance exceeding analysts’ expectations and a decent beat of analysts’ revenue estimates.

Is Quest a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Quest’s revenue to grow 6.3% year on year, slowing from the 12.1% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Quest has a history of exceeding Wall Street’s expectations.

With Quest being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for healthcare providers & services stocks. However, there has been positive investor sentiment in the segment, with share prices up 9.1% on average over the last month. Quest is up 5.1% during the same time .

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.